Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Preferred Stock Liabilities: 2019

  • 4D Molecular Therapeutics' Preferred Stock Liabilities was N/A to $103.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was $103.0 million, marking a year-over-year change of. This contributed to the annual value of $103.0 million for FY2019, which is N/A change from last year.
  • According to the latest figures from Q4 2019, 4D Molecular Therapeutics' Preferred Stock Liabilities is $103.0 million.
  • 4D Molecular Therapeutics' 5-year Preferred Stock Liabilities high stood at $103.0 million for Q4 2019, and its period low was $103.0 million during Q4 2019.
  • For the 1-year period, 4D Molecular Therapeutics' Preferred Stock Liabilities averaged around $103.0 million, with its median value being $103.0 million (2019).